Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells

Baird Chautauqua International Growth Fund underperformed its benchmark as stock selection in health care and consumer discretionary detracted most from relative returns. Fanuc reported September quarter results that beat consensus estimates, raising full-year operating profit guidance by 10% on demand recovery and improved utilization rates. Sea Limited reported September quarter results that beat consensus estimates, with revenue growing 38% and gross merchandise value growing 28%.

Seeking Alpha • Feb 13, 2026

Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?

Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.

Zacks Investment Research • Feb 12, 2026

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

GlobeNewsWire • Feb 11, 2026

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies

GlobeNewsWire • Feb 10, 2026

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported upbeat fourth-quarter earnings.

Benzinga • Feb 2, 2026

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing

GlobeNewsWire • Feb 2, 2026

Regeneron: Expect Double-Digit Growth In 2026

Regeneron is poised for double-digit revenue and EPS growth in 2026, driven by Dupixent and reduced Eylea headwinds. Dupixent's robust expansion and pipeline successors support Regeneron's long-term growth and mitigate post-exclusivity risks. Eylea's decline is moderating, aided by increased patient support and anticipated label expansions.

Seeking Alpha • Jan 31, 2026

Regeneron beats quarterly profit estimates on Dupixent strength

U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.

Reuters • Jan 30, 2026

Regeneron bets added cholesterol benefit will help its obesity drug stand out

Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly crowded obesity market.

Reuters • Jan 30, 2026

Regeneron Handily Beat Fourth-Quarter Forecasts — Here's Why Shares Fell

Regeneron stock took a hit early Friday on its higher-than-expected 2026 cost outlook following a fourth-quarter beat.

Investors Business Daily • Jan 30, 2026